Furthermore, exenatide has been demonstrated to inhibit the pro-inflammatory phenotypes of human PBMC-derived monocytes/macrophages through its regulatory effects on key signaling pathways, including mitogen-activated protein kinase (MAPK), NF-B and CCAAT/enhancer-binding protein beta (C/EBP) [90]
Providers may slow titration, hold a dose steady, or step back temporarily depending on symptoms and response
Approval applies to a particular drug, formulation, dosage, manufacturer, and indication
However, no research directly compares continuous use versus cycling protocols (such as 12 weeks on, 4-8 weeks off), leaving optimal long-term strategies somewhat uncertain